Oxaliplatin and Topotecan in Advance Ovarian Cancer

National Cancer Institute (NCI)

Status and phase

Terminated

Phase 2

Conditions

Recurrent Ovarian Epithelial Cancer

Treatments

Drug: oxaliplatin

Drug: topotecan

Study type

Interventional

Funder types

NIH

Identifiers

NCT00313612

NCI-2009-00053

NYU 03-67 (Other Identifier)

N01CM62204 (U.S. NIH Grant/Contract)

Details and patient eligibility

About

This phase II trial is studying how well giving oxaliplatin together with topotecan works in treating patients with ovarian epithelial cancer, primary peritoneal cancer, or fallopian tube cancer. Drugs used in chemotherapy, such as oxaliplatin and topotecan, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. Giving more than one drug (combination chemotherapy) may kill more tumor cells.

Full description

PRIMARY OBJECTIVES:

I. Estimate the overall clinical response rate (complete and partial responses) in patients with previously treated ovarian epithelial, primary peritoneal, or fallopian tube cancer treated with oxaliplatin and topotecan.

II. Determine the toxic effects in patients treated with this regimen.

SECONDARY OBJECTIVES:

I. Estimate the time to progression and overall clinical response duration in patients treated with this regimen.

OUTLINE: This is an open-label, multicenter study. Patients are stratified according to response to prior platinum therapy (resistant vs sensitive).

Patients receive oxaliplatin IV over 2 hours on days 1 and 15 and topotecan IV continuously on days 1-14. Treatment repeats every 28 days for up to 6 courses in the absence of disease progression or unacceptable toxicity.

After completion of study treatment, patients are followed at 30 days.

Enrollment

39 patients

Sex

Female

Ages

18+ years old

Volunteers

No Healthy Volunteers

Inclusion criteria

Histologically or cytologically confirmed ovarian epithelial, primary peritoneal, or fallopian tube cancer
Meets 1 of the following criteria for response to prior platinum-based therapy:
- Platinum-resistant disease, defined as a disease-free interval of < 6 months after prior platinum-based therapy OR progressive disease on a platinum-containing regimen
- Platinum-sensitive disease, defined as a disease-free interval of > 6 months after prior platinum-based therapy
Measurable or evaluable disease: Measurable disease is characterized as lesions reproducibly measurable in 1 dimension; evaluable disease is defined as known disease with CA125 levels > 50 U/mL on 2 occasions >= 1 week apart
Previously treated with a taxane and platinum-based regimen, only 1 prior platinum-based regimen, including IV or intraperitoneal consolidation, one additional non-platinum and non-topotecan chemotherapy regimen allowed
Life expectancy >= 4 months
Total bilirubin =< 1.5 times upper limit of normal (ULN)
AST =< 2.5 times ULN (5 times ULN if liver metastases are present)
Creatinine =< 1.5 times ULN AND creatinine clearance > 40 mg/dL

Exclusion criteria

No presence of any other active cancer
No uncontrolled intercurrent illness, including the following:
- Infection
- Symptomatic congestive heart failure
- Unstable angina pectoris
- Cardiac arrhythmia
No history of severe allergy to platinum compounds
- (Mild reaction (skin only) allowed provided a negative skin test is obtained)
No history of allergic reaction to appropriate antiemetics (e.g., 5HT3 antagonists)
Recovered from prior chemotherapy
At least 2 weeks since prior radiotherapy and recovered
At least 4 weeks since prior investigational drugs
No prior radiotherapy to the whole pelvic field
No unresolved sequelae resulting from any surgical procedures
No concurrent colony-stimulating factors (e.g., filgrastim [G-CSF] or sargramostim [GM-CSF]) during topotecan infusion
No concurrent participation in another investigational trial
No other concurrent investigational agents
No other concurrent anticancer therapy